Susquehanna International Group
ABOS icon

Susquehanna International Group’s Acumen Pharmaceuticals ABOS Stock Holding History

Susquehanna International Group’s Portfolio ABOS Stock Details ABOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$132K Buy
+56,000
New +$143K ﹤0.01% 12134
2025
Q3 		– Sell
-17,200
Closed -$20K – 12234
2025
Q2 		$20K Buy
+17,200
New +$18.5K ﹤0.01% 12335
2024
Q4 		– Sell
-54,800
Closed -$136K – 12073
2024
Q3 		$136K Sell
54,800
-104,800
-66% -$284K ﹤0.01% 10828
2024
Q2 		$386K Sell
159,600
-82,000
-34% -$261K ﹤0.01% 8880
2024
Q1 		$978K Buy
241,600
+82,700
+52% +$312K ﹤0.01% 6973
2023
Q4 		$610K Buy
158,900
+53,100
+50% +$158K ﹤0.01% 8177
2023
Q3 		$439K Sell
105,800
-35,300
-25% -$218K ﹤0.01% 8536
2023
Q2 		$679K Buy
141,100
+98,800
+234% +$473K ﹤0.01% 7593
2023
Q1 		$172K Buy
42,300
+7,100
+20% +$37.1K ﹤0.01% 10786
2022
Q4 		$190K Sell
35,200
-85,200
-71% -$572K ﹤0.01% 10206
2022
Q3 		$1.21M Buy
+120,400
New +$691K ﹤0.01% 6144

Other funds holding ABOS

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
KIA
Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Susquehanna International Group's ABOS Position: Q1 2026 in Review

Susquehanna International Group increased its Acumen Pharmaceuticals (ABOS) stake by 61% in Q1 2026, buying an estimated $582K and bringing the position to 601,476 shares worth $1.42M. The position accounts for ﹤0.01% of the portfolio, ranked #7029.

Susquehanna International Group first reported a position in ABOS in Q2 2022 and has held it in 15 quarters since. The position peaked at $1.92M in Q4 2023. 84 funds tracked by Wall St. Rank hold ABOS as of Q1 2026.

  • Susquehanna International Group held 601,476 shares of Acumen Pharmaceuticals worth $1.42M as of Q1 2026.
  • Susquehanna International Group bought 228,278 Acumen Pharmaceuticals shares in Q1 2026, an estimated $582K.
  • Acumen Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #7029 holding.
  • Susquehanna International Group first reported a position in Acumen Pharmaceuticals in Q2 2022 and has held it in 15 quarters since.
  • Susquehanna International Group's Acumen Pharmaceuticals position peaked at $1.92M in Q4 2023.
  • 84 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.